Literature DB >> 18043108

Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.

Yih-Huei Uen1, Shiu-Ru Lin, Deng-Chyang Wu, Yu-Chung Su, Jeng-Yih Wu, Tian-Lu Cheng, Chin-Wen Chi, Jaw-Yuan Wang.   

Abstract

OBJECTIVE: The aim of this study was to determine whether our constructed high-sensitivity colorimetric membrane-array method could detect circulating tumor cells (CTCs) in the peripheral blood of stage II colorectal cancer (CRC) patients and so identify a subgroup of patients who are at high risk for relapse. SUMMARY BACKGROUND DATA: Adjuvant chemotherapy is not routinely recommended in patients diagnosed with UICC stage II CRC. However, up to 30% of patients with stage II disease relapse within 5 years of surgery from recurrent or metastatic disease. The identification of reliable prognostic factors for high-risk stage II CRC patients is imperative.
METHODS: Membrane-arrays consisting of a panel of mRNA markers that included human telomerase reverse transcription (hTERT), cytokeratin-19 (CK-19), cytokeratin-20 (CK-20), and carcinoembryonic antigen (CEA) mRNA were used to detect CTCs in the peripheral blood of 194 stage II CRC patients who underwent potentially curative (R0) resection between January 2002 and December 2005. Digoxigenin (DIG)-labeled cDNA were amplified by RT-PCR from the peripheral blood samples, which were then hybridized to the membrane-array. All patients were followed up regularly, and their outcomes were investigated completely.
RESULTS: Overall, 53 of 194 (27.3%) stage II patients were detected with the expression of all 4 mRNA markers using the membrane-array method. After a median follow up of 40 months, 56 of 194 (28.9%) developed recurrence/metastases postoperatively. Univariately, postoperative relapse was significantly correlated with the depth of invasion (P < 0.001), the presence of vascular invasion (P < 0.001), the presence of perineural invasion (P = 0.048), the expression of all 4 mRNA markers (P < 0.001), and the number of examined lymph nodes (P = 0.031). Meanwhile, using a multivariate logistic regression analysis, T4 depth of tumor invasion (P = 0.013), the presence of vascular invasion (P = 0.032), and the expression of all 4 mRNA markers (P < 0.001) were demonstrated to be independent predictors for postoperative relapse. Combination of the depth of tumor invasion, vascular invasion, and all 4 mRNA markers as predictors of postoperative relapse showed that patients with any 1 positive predictor had a hazard ratio of about 27-fold to develop postoperative relapse (P < 0.001; 95% CI = 11.42-64.40). The interval between the detection of all 4 positive molecular markers and subsequently developed postoperative relapse ranged from 4 to 10 months (median: 7 months). Furthermore, the expression of all 4 mRNA markers in all stage II CRC patients, or either stage II colon or rectal cancer patients were strongly correlated with poorer relapse-free survival rates by survival analyses (all P < 0.001).
CONCLUSIONS: The pilot study suggests that the constructed membrane-array method for the detection of CTCs is a potential auxiliary tool to conventional clinicopathological variables for the prediction of postoperative relapse in stage II CRC patients who have undergone curative resection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18043108     DOI: 10.1097/SLA.0b013e318142d918

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

1.  Time to Redefine the Role of Routine Combined-Modality Therapy for Invasive Stage-II/III Rectal Cancer?

Authors:  Lily L Lai; Charles R Thomas
Journal:  Gastrointest Cancer Res       Date:  2009-03

Review 2.  Clinical impact of minimal cancer cell detection in various colorectal cancer specimens.

Authors:  Kazuhiko Yoshimatsu; Hajime Yokomizo; Yoshihiko Naritaka
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

3.  Amarogentin Induces Apoptosis of Liver Cancer Cells via Upregulation of p53 and Downregulation of Human Telomerase Reverse Transcriptase in Mice.

Authors:  Chun Huang; Runqin Li; Yinglin Zhang; Jianping Gong
Journal:  Technol Cancer Res Treat       Date:  2016-07-11

4.  Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.

Authors:  Aikaterini Tsouma; Chrysanthi Aggeli; Panagiotis Lembessis; George-N Zografos; Dimitris-P Korkolis; Dimitrios Pectasides; Maria Skondra; Nikolaos Pissimissis; Anastasia Tzonou; Michael Koutsilieris
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 5.  Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review.

Authors:  G Peach; C Kim; E Zacharakis; S Purkayastha; P Ziprin
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

6.  Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen.

Authors:  Caiyun Liu; Bin Dong; Aiping Lu; Like Qu; Xiaofang Xing; Lin Meng; Jian Wu; Y Eric Shi; Chengchao Shou
Journal:  BMC Cancer       Date:  2010-07-07       Impact factor: 4.430

Review 7.  Recent approaches to identifying biomarkers for high-risk stage II colon cancer.

Authors:  Takashi Akiyoshi; Takashi Kobunai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2012-09-09       Impact factor: 2.549

Review 8.  Molecular biomarkers for the detection of metastatic colorectal cancer cells.

Authors:  Hidenori Kamiyama; Hiroshi Noda; Fumio Konishi; Toshiki Rikiyama
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 9.  Cancer micrometastases.

Authors:  Klaus Pantel; Catherine Alix-Panabières; Sabine Riethdorf
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

10.  Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas.

Authors:  Lukasz-Filip Grochola; Thomas Greither; Helge W Taubert; Peter Möller; Uwe Knippschild; Andrej Udelnow; Doris Henne-Bruns; Peter Würl
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.